Elucidating drug resistance in human fungal pathogens

Future Microbiology

Volumn 9, Issue 4, 2014, Pages 523-542

  Xie, Jinglin Lucy ^a   Polvi, Elizabeth J ^a   Shekhar Guturja, Tanvi ^a   Cowen, Leah E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aspergillus fumigatus; azoles; Candida albicans; Cryptococcus neoformans; drug resistance; echinocandins; polyenes

Indexed keywords

ABC TRANSPORTER; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPID; MULTIDRUG RESISTANCE PROTEIN; POLYENE; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CELLULAR STRESS RESPONSE; CRYPTOCOCCUS NEOFORMANS; DRUG RESPONSE; GENETIC SCREENING; MYCOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; AZOLES; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MYCOSES; POLYENES;

EID: 84900319598     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.18     Document Type: Review

References (158)

1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci. Transl. Med. 4(165), 165rv113 (2012).
2. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36(1), 1-53 (2010).
3. Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 75(2), 213-267 (2011).
4. Lin X, Heitman J. The biology of the Cryptococcus neoformans species complex. Annu. Rev. Microbiol. 60, 69-105 (2006).
5. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23(4), 525-530 (2009).
6. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32(3), 358-366 (2001).
7. CDC. Antibiotic Resistance Threats in the United States, 2013. US Department of Health and Human Services. CDC, GA, USA (2013).
8. Cowen LE, Steinbach WJ. Stress, drugs and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot. Cell 7(5), 747-764 (2008).
9. Cowen LE. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol. 6(3), 187-198 (2008).
10. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy 28(5), 614-645 (2008).
11. Te Welscher YM, Van Leeuwen MR, De Kruijff B, Dijksterhuis J, Breukink E. Polyene antibiotic that inhibits membrane transport proteins. Proc. Natl Acad. Sci. USA 109(28), 11156-11159 (2012).
12. Denning DW. Echinocandin antifungal drugs. Lancet 362(9390), 1142-1151 (2003).
13. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 11(6), 272-279 (2003).
14. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. 9(9), 719-727 (2010).
15. Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S. Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol. 11(10), e1001692 (2013).
16. Chapeland-Leclerc F, Hennequin C, Papon N et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 54(3), 1360-1362 (2010).
17. Lewis RE, Viale P, Kontoyiannis DP. The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence 3(4), 368-376 (2012).
18. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125(Suppl. 1), S3-S13 (2012).
19. Bueid A, Howard SJ, Moore CB et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65(10), 2116-2118 (2010).
20. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9(12), 789-795 (2009).
21. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J. Infect. 56(2), 126-129 (2008).
22. Arendrup MC, Sulim S, Holm A et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J. Clin. Microbiol. 49(9), 3300-3308 (2011).
23. Singh-Babak SD, Babak T, Diezmann S et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog. 8(5), e1002718 (2012).
24. Pang KA, Godet C, Fekkar A et al. Breakthrough invasive mould infections in patients treated with caspofungin. J. Infect. 64(4), 424-429 (2012).
25. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253(5022), 905-909 (1991).
26. Douglas CM, Marrinan JA, Li W, Kurtz MB. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J. Bacteriol. 176(18), 5686-5696 (1994).
27. Van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob. Agents Chemother. 46(11), 3394-3400 (2002).
28. Huang Z, Chen K, Zhang J et al. A functional variomics tool for discovering drug-resistance genes and drug targets. Cell Rep. 3(2), 577-585 (2013).
29. Hill JA, Ammar R, Torti D, Nislow C, Cowen LE. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet. 9(4), e1003390 (2013).
30. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 5(7), e1000532 (2009).
31. Lesage G, Sdicu AM, Menard P, Shapiro J, Hussein S, Bussey H. Analysis of beta-1,3- glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. Genetics 167(1), 35-49 (2004).
32. Kaur R, Castano I, Cormack BP. Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob. Agents Chemother. 48(5), 1600-1613 (2004).
33. Lafayette SL, Collins C, Zaas AK et al. PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog. 6(8), e1001069 (2010).
34. Giaever G, Shoemaker DD, Jones TW et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21(3), 278-283 (1999).
35. Hoon S, Smith AA, Wallace IM et al. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat. Chem. Biol. 4(8), 498-506 (2008).
36. Hitchcock CA, Barrett-Bee KJ, Russell NJ. The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. J. Med. Vet. Mycol. 25(1), 29-37 (1987).
37. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39(11), 2378-2386 (1995).
38. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL. Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol. Lett. 131(3), 337-341 (1995).
39. Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Moereels H, Janssen PA. Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals. Biochem. Soc. Trans. 18(1), 56-59 (1990).
40. Walker LA, Munro CA, De Bruijn I, Lenardon MD, Mckinnon A, Gow NA. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 4(4), e1000040 (2008).
41. Lee KK, Maccallum DM, Jacobsen MD et al. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob. Agents Chemother. 56(1), 208-217 (2012).
42. Reinoso-Martin C, Schuller C, Schuetzer- Muehlbauer M, Kuchler K. The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot. Cell 2(6), 1200-1210 (2003).
43. Hoehamer CF, Cummings ED, Hilliard GM, Rogers PD. Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents. Antimicrob. Agents Chemother. 54(5), 1655-1664 (2010).
44. Singh A, Yadav V, Prasad R. Comparative lipidomics in clinical isolates of Candida albicans reveal crosstalk between mitochondria, cell wall integrity and azole resistance. PLoS ONE 7(6), e39812 (2012).
45. Coen M, Bodkin J, Power D et al. Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy. Antimicrob. Agents Chemother. 50(12), 4018-4026 (2006).
46. Kitano H. Computational systems biology. Nature 420(6912), 206-210 (2002).
47. Baginsky S, Hennig L, Zimmermann P, Gruissem W. Gene expression analysis, proteomics, and network discovery. Plant Physiol. 152(2), 402-410 (2010).
48. Marichal P, Koymans L, Willemsens S et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145 (Pt 10), 2701-2713 (1999).
49. Lamb DC, Kelly DE, White TC, Kelly SL. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob. Agents Chemother. 44(1), 63-67 (2000).
50. Xiang MJ, Liu JY, Ni PH et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res. 13(4), 386-393 (2013).
51. Ji H, Zhang W, Zhou Y et al. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J. Med. Chem. 43(13), 2493-2505 (2000).
52. Du W, Coaker M, Sobel JD, Akins RA. Shuttle vectors for Candida albicans: control of plasmid copy number and elevated expression of cloned genes. Curr. Genet. 45(6), 390-398 (2004).
53. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11(2), 382-402 (1998).
54. Silver PM, Oliver BG, White TC. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3(6), 1391-1397 (2004).
55. Flowers SA, Barker KS, Berkow EL et al. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot. Cell 11(10), 1289-1299 (2012).
56. Rodero L, Mellado E, Rodriguez AC et al. G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob. Agents Chemother. 47(11), 3653-3656 (2003).
57. Mann PA, Parmegiani RM, Wei SQ et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob. Agents Chemother. 47, 577-581 (2003).
58. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47, 1120-1124 (2003).
59. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, Mcnicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48(2), 568-574 (2004).
60. Balashov SV, Gardiner R, Park S, Perlin DS. Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole. J. Clin. Microbiol. 43, 214-222 (2005).
61. Mellado E, Garcia-Effron G, Alczar-Fuoli L et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51, 1897-1904 (2007).
62. Snelders E, Van Der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5(11), e219 (2008).
63. Mortensen KL, Mellado E, Lass-Florl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54(11), 4545-4549 (2010).
64. Van Der Linden JW, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17(10), 1846-1854 (2011).
65. Sterling TR, Merz WG. Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist. Updat. 1(3), 161-165 (1998).
66. Vandeputte P, Tronchin G, Berges T, Hennequin C, Chabasse D, Bouchara JP. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob. Agents Chemother. 51(3), 982-990 (2007).
67. Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348(9040), 1523-1524 (1996).
68. Kelly SL, Lamb DC, Kelly DE et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett. 400(1), 80-82 (1997).
69. Eddouzi J, Parker JE, Vale-Silva LA et al. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob. Agents Chemother. 57(7), 3182-3193 (2013).
70. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 710-718 (2000).
71. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43(5), 2163-2167 (2005).
72. Kelly SL, Lamb DC, Taylor M, Corran AJ, Baldwin BC, Powderly WG. Resistance to amphotericin B associated with defective sterol delta 8-7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122(1-2), 39-42 (1994).
73. Ko YJ, Yu YM, Kim GB et al. Remodeling of global transcription patterns of Cryptococcus neoformans genes mediated by the stress-activated HOG signaling pathways. Eukaryot. Cell 8(8), 1197-1217 (2009).
74. Moore CB, Walls CM, Denning DW. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob. Agents Chemother. 44(2), 441-443 (2000).
75. Blum G, Perkhofer S, Haas H et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother. 52(4), 1553-1555 (2008).
76. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10(3), 121-130 (2007).
77. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50(6), 2058-2063 (2006).
78. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49(8), 3264-3273 (2005).
79. Zimbeck AJ, Iqbal N, Ahlquist AM et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from US population-based surveillance. Antimicrob. Agents Chemother. 54(12), 5042-5047 (2010).
80. Johnson ME, Katiyar SK, Edlind TD. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob. Agents Chemother. 55(8), 3774-3781 (2011).
81. Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol. 43(Suppl. 1), 299-305 (2005).
82. Rocha EM, Garcia-Effron G, Park S, Perlin DS. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 51, 4174-4176 (2007).
83. Thompson JR, Douglas CM, Li W et al. A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. 181(2), 444-453 (1999).
84. Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob. Agents Chemother. 49(7), 2851-2856 (2005).
85. Cannon RD, Lamping E, Holmes AR et al. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22(2), 291-321 (2009).
86. Perea S, Lopez-Ribot JL, Kirkpatrick WR et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45(10), 2676-2684 (2001).
87. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143(Pt 2), 405-416 (1997).
88. Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3(6), 1639-1652 (2004).
89. Coste AT, Crittin J, Bauser C, Rohde B, Sanglard D. Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot. Cell 8(8), 1250-1267 (2009).
90. Siikala E, Rautemaa R, Richardson M, Saxen H, Bowyer P, Sanglard D. Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J. Antimicrob. Chemother. 65(12), 2505-2513 (2010).
91. Sanglard D. Resistance to antifungal drugs. In: Essentials of Clinical Mycology, Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (Eds). Springer, NY, USA, 135-151 (2011).
92. Liu TT, Znaidi S, Barker KS et al. Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. Eukaryot. Cell 6(11), 2122-2138 (2007).
93. Schillig R, Morschhauser J. Analysis of a fungus-specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activation. Mol. Microbiol. 89(5), 1003-1017 (2013).
94. Posteraro B, Sanguinetti M, Sanglard D et al. Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol. Microbiol. 47(2), 357-371 (2003).
95. Sanguinetti M, Posteraro B, La Sorda M et al. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans. Infect. Immun. 74(2), 1352-1359 (2006).
96. Slaven JW, Anderson MJ, Sanglard D et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet. Biol. 36, 199-206 (2002).
97. Dunkel N, Blass J, Rogers PD, Morschhauser J. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69(4), 827-840 (2008).
98. Morschhauser J, Barker KS, Liu TT, Bla BWJ, Homayouni R, Rogers PD. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3(11), e164 (2007).
99. Schubert S, Popp C, Rogers PD, Morschhauser J. Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1. Eukaryot. Cell 10(8), 1110-1121 (2011).
100. Thornewell SJ, Peery RB, Skatrud PL. Cloning and characterization of CneMDR1: a Cryptococcus neoformans gene encoding a protein related to multidrug resistance proteins. Gene 201(1-2), 21-29 (1997).
101. Da Silva Ferreira ME, Capellaro JL, Dos Reis Marques E et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob. Agents Chemother. 48(11), 4405-4413 (2004).
102. Selmecki A, Forche A, Berman J. Genomic plasticity of the human fungal pathogen Candida albicans. Eukaryot. Cell 9(7), 991-1008 (2010).
103. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313(5785), 367-370 (2006).
104. Coste A, Selmecki A, Forche A et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6(10), 1889-1904 (2007).
105. Selmecki AM, Dulmage K, Cowen LE, Anderson JB, Berman J. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet. 5(10), e1000705 (2009).
106. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6(4), e1000848 (2010).
107. Ngamskulrungroj P, Chang Y, Hansen B, Bugge C, Fischer E, Kwon-Chung KJ. Characterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans. PLoS ONE 7(3), e33022 (2012).
108. Niimi K, Monk BC, Hirai A et al. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J. Antimicrob. Chemother. 65(5), 842-852 (2010).
109. Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog. 5(8), e1000471 (2009).
110. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309(5744), 2185-2189 (2005).
111. Cowen LE, Singh SD, Kohler JR et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl Acad. Sci. USA 106(8), 2818-2823 (2009).
112. Cowen LE, Carpenter AE, Matangkasombut O, Fink GR, Lindquist S. Genetic architecture of Hsp90-dependent drug resistance. Eukaryot. Cell 5(12), 2184-2188 (2006).
113. Shapiro RS, Zaas AK, Betancourt-Quiroz M, Perfect JR, Cowen LE. The Hsp90 co-chaperone Sgt1 governs Candida albicans morphogenesis and drug resistance. PLoS ONE 7(9), e44734 (2012).
114. Robbins N, Leach MD, Cowen LE. Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance. Cell Rep. 2(4), 878-888 (2012).
115. Morio F, Pagniez F, Lacroix C, Miegeville M, Le Pape P. Amino acid substitutions in the Candida albicans sterol Delta5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J. Antimicrob. Chemother. 67(9), 2131-2138 (2012).
116. Vale-Silva LA, Coste AT, Ischer F et al. Azole resistance by loss of function of the sterol delta(5),(6)-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob. Agents Chemother. 56(4), 1960-1968 (2012).
117. Munro CA, Selvaggini S, De Bruijn I et al. The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol. Microbiol. 63(5), 1399-1413 (2007).
118. Lee H, Khanal Lamichhane A, Garraffo HM, Kwon-Chung KJ, Chang YC, Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans. Mol. Microbiol 84(1), 130-146 (2012).
119. Walker LA, Gow NA, Munro CA. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob. Agents Chemother. 57(1), 146-154 (2013).
120. White TC, Silver PM. Regulation of sterol metabolism in Candida albicans by the UPC2 gene. Biochem. Soc. Trans. 33(Pt 5), 1215-1218 (2005).
121. Gallo-Ebert C, Donigan M, Stroke IL et al. Novel antifungal drug discovery based on targeting pathways regulating the fungal-conserved Upc2 rranscription factor. Antimicrob. Agents Chemother. 58(1), 258-266 (2014).
122. Blatzer M, Barker BM, Willger SD et al. SREBP coordinates iron and ergosterol homeostasis to mediate triazole drug and hypoxia responses in the human fungal pathogen Aspergillus fumigatus. PLoS Genet. 7(12), e1002374 (2011).
123. Chang YC, Ingavale SS, Bien C, Espenshade P, Kwon-Chung KJ. Conservation of the sterol regulatory element-binding protein pathway and its pathobiological importance in Cryptococcus neoformans. Eukaryot. Cell 8(11), 1770-1779 (2009).
124. Mukhopadhyay K, Prasad T, Saini P, Pucadyil TJ, Chattopadhyay A, Prasad R. Membrane sphingolipid-ergosterol interactions are important determinants of multidrug resistance in Candida albicans. Antimicrob. Agents Chemother. 48(5), 1778-1787 (2004).
125. Healey KR, Katiyar SK, Raj S, Edlind TD. CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction. Mol. Microbiol. 86(2), 303-313 (2012).
126. Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D. Contribution of CgPDR1- regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS ONE 6(3), e17589 (2011).
127. Sun N, Fonzi W, Chen H, She X, Zhang L, Calderone R. Azole susceptibility and transcriptome profiling in Candida albicans mitochondrial electron transport chain complex I mutants. Antimicrob. Agents Chemother. 57(1), 532-542 (2013).
128. Shingu-Vazquez M, Traven A. Mitochondria and fungal pathogenesis: drug tolerance, virulence, and potential for antifungal therapy. Eukaryot. Cell 10(11), 1376-1383 (2011).
129. Blankenship JR, Mitchell AP. How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 9(6), 588-594 (2006).
130. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71(8), 4333-4340 (2003).
131. Fanning S, Mitchell AP. Fungal biofilms. PLoS Pathog. 8(4), e1002585 (2012).
132. Nobile CJ, Nett JE, Hernday AD et al. Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol. 7(6), e1000133 (2009).
133. Nett JE, Sanchez H, Cain MT, Andes DR. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202(1), 171-175 (2010).
134. Nett JE, Sanchez H, Cain MT, Ross KM, Andes DR. Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. Eukaryot. Cell 10(12), 1660-1669 (2011).
135. Robbins N, Uppuluri P, Nett J et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 7(9), e1002257 (2011).
136. Desai JV, Bruno VM, Ganguly S et al. Regulatory role of glycerol in Candida albicans biofilm formation. MBio 4(2), e00637-e00612 (2013).
137. Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. An in vitro study of sequential fluconazole/caspofungin treatment against Candida albicans biofilms. Antimicrob. Agents Chemother. 58(2), 1183-1186 (2014).
138. Rajendran R, Mowat E, Mcculloch E et al. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob. Agents Chemother. 55(5), 2092-2097 (2011).
139. Rajendran R, Williams C, Lappin DF, Millington O, Martins M, Ramage G. Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms. Eukaryot. Cell 12(3), 420-429 (2013).
140. Taff HT, Mitchell KF, Edward JA Andes DR. Mechanisms of Candida biofilm drug resistance. Future Microbiol. 8(10), 1325-1337 (2013).
141. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 21(8 Pt 2), 149S-164S (2001).
142. Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat. Rev. Cancer 12(7), 494-501 (2012).
143. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7(12), 864-874 (2009).
144. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. Advancing the development of tuberculosis therapy. Nat. Rev. 11(3), 171-172 (2012).
145. Johnson MD, Macdougall C, Ostrosky- Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob. Agents Chemother. 48(3), 693-715 (2004).
146. Wurtele H, Tsao S, Lepine G et al. Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nat. Med. 16(7), 774-780 (2010).
147. Blankenship JR, Steinbach WJ, Perfect JR, Heitman J. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr. Opin. Investig. Drugs 4(2), 192-199 (2003).
148. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat. Rev. Microbiol. 5(6), 418-430 (2007).
149. Pizarro JC, Hills T, Senisterra G et al. Exploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug design. PLoS Negl. Trop. Dis. 7(10), e2492 (2013).
150. Hast MA, Nichols CB, Armstrong SM et al. Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens. J. Biol. Chem. 286(40), 35149-35162 (2011).
151. Filler SG
152. Zhu W, Phan QT, Boontheung P, Solis NV, Loo JA, Filler SG. EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection. Proc. Natl Acad. Sci. USA 109(35), 14194-14199 (2012).
153. Cutler JE, Deepe GS Jr, Klein BS. Advances in combating fungal diseases. vaccines on the threshold. Nat. Rev. Microbiol. 5(1), 13-28 (2007).
154. Casadevall A, Pirofski LA. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe 11(5), 447-456 (2012).
155. Delsing CE, Bleeker-Rovers CP, Kullberg BJ, Netea MG. Treatment of candidiasis: insights from host genetics. Expert Rev. Anti Infect. Ther. 10(8), 947-956 (2012).
156. Brown GD, Netea MG. Exciting developments in the immunology of fungal infections. Cell Host Microbe 11(5), 422-424 (2012).
157. Roy RM, Klein BS. Dendritic cells in antifungal immunity and vaccine design. Cell Host Microbe 11(5), 436-446 (2012).
158. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2(4), e35 (2006).